Anavex Life Sciences Receives Nasdaq Delinquency Notice Over Delayed 10-Q Filing

On May 20, 2026, Anavex Life Sciences Corp. received a delinquency notification letter from the Nasdaq Listing Qualifications Department. The notice was issued because the company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, in violation of Nasdaq Listing Rule 5250(c)(1). This notification does not have an immediate effect on the listing of Anavex's common stock (AVXL), which continues to trade on The Nasdaq Global Select Market. Anavex has until July 20, 2026, to submit a formal plan to regain compliance. If Nasdaq accepts this plan, the company may be granted an extension of up to 180 calendar days from the original filing due date—specifically until November 16, 2026—to file the delinquent report and regain compliance. If the plan is rejected, the company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel. Anavex stated it is working to complete the filing and submit the required compliance plan.